文献速递眼底病与葡萄膜炎

口服伐昔洛韦与静脉阿昔洛韦治疗急性视网膜坏死的比较

Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir.
PubMed 文献 · Am J Ophthalmol · 2018-02-12

该回顾性比较干预病例系列纳入1992至2016年间在Moorfields眼科医院治疗的62例(68眼)急性视网膜坏死(ARN)患者,比较初始静脉阿昔洛韦(33例)与口服伐昔洛韦(29例)的视力结局。5年随访数据显示两组最佳矫正视力变化无显著差异(P=0.16),严重视力丧失率(46% vs 59%,P=0.18)、保持良好视力率(28% vs 31%,P=0.80)及视网膜脱离率(62% vs 66%,P=0.67)均无显著差异。作者认为口服伐昔洛韦在ARN管理中与静脉治疗临床等效,可作为可接受的替代方案。

要点

  • 口服伐昔洛韦与静脉阿昔洛韦治疗ARN后5年最佳矫正视力变化无显著差异(P=0.16)。
  • 两组严重视力丧失率(46% vs 59%,P=0.18)和保持良好视力率(28% vs 31%,P=0.80)均无显著差异。
  • 视网膜脱离总发生率63%,两组间无显著差异(62% vs 66%,P=0.67),屏障激光和玻璃体腔抗病毒治疗对脱离率无影响。

核心结论

  • 口服伐昔洛韦在ARN管理中与静脉治疗临床等效。
  • 口服伐昔洛韦作为门诊治疗——联合或不联合玻璃体腔膦甲酸钠——可考虑作为静脉治疗所需住院治疗的可接受替代方案。

研究设计与样本

  • 回顾性、比较性、干预性病例系列。
  • 纳入1992至2016年间在Moorfields眼科医院(英国)经医院电子数据库识别的62例(68眼)ARN患者。
  • 排除标准包括患者记录不足或随访不足(<150天)。
  • 56例为单侧ARN,6例为双侧ARN。
  • 诊断时接受静脉阿昔洛韦者33例,接受口服伐昔洛韦者29例,比较最佳矫正视力、视网膜脱离、严重视力丧失及其他并发症等结局,并评估辅助玻璃体腔抗病毒治疗和预防性屏障激光治疗的影响。

主要发现

  • 5年随访数据中,初始静脉治疗眼与口服治疗眼的最佳矫正视力变化无显著差异(P=0.16)。
  • 两组严重视力丧失率分别为46%和59%,无差异(P=0.18)。
  • 两组保持良好视力率分别为28%和31%,无差异(P=0.80)。
  • 视网膜脱离发生于63%的病例,两组间无差异(分别为62%和66%,P=0.67)。
  • 屏障激光和玻璃体腔治疗在两组中均对 retinal detachment 率无影响。

关键数值与推荐

  • 最佳矫正视力变化:静脉治疗眼 vs 口服治疗眼,5年随访,P=0.16(无显著差异)。
  • 严重视力丧失率:静脉组46% vs 口服组59%,P=0.18(无显著差异)。
  • 保持良好视力率:静脉组28% vs 口服组31%,P=0.80(无显著差异)。
  • 视网膜脱离率:静脉组62% vs 口服组66%,P=0.67(无显著差异);总发生率63%。

临床怎么用

  • 作者认为口服伐昔洛韦作为门诊治疗——联合或不联合玻璃体腔膦甲酸钠——可考虑作为静脉治疗所需住院治疗的可接受替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the visual outcomes of patients with acute retinal necrosis (ARN) treated initially with intravenous acyclovir vs oral valacyclovir therapy. DESIGN: Retrospective, comparative, interventional case series. METHODS: Sixty-two patients (68 eyes) with ARN, treated at Moorfields Eye Hospital (United Kingdom) between 1992 and 2016, were identified through the hospital's electronic database. Exclusion criteria included insufficient patient records or follow-up (<150 days). Fifty-six patients had unilateral ARN, while 6 had bilateral ARN. Patients who received intravenous acyclovir on diagnosis (n = 33) were compared with patients treated with oral valacyclovir (n = 29) across outcomes including best-corrected visual acuity, retinal detachment, severe vision loss, and other complications. The impact of adjunctive intravitreal antiviral and prophylactic barrier laser treatment was also assessed. RESULTS: Change in best-corrected visual acuity was not significantly different for eyes treated initially with intravenous therapy vs oral therapy over 5 years of follow-up data (P = .16). There was no difference in the rates of severe vision loss between the 2 groups (46% and 59%, respectively, P = .18), or of those eyes retaining good vision (28% vs 31%, respectively, P = .80). Retinal detachment occurred in 63% of cases and did not differ across treatment groups (62% vs 66%, respectively, P = .67). Barrier laser and intravitreal therapy had no effect on retinal detachment rate in either group. CONCLUSION: Oral valacyclovir is clinically equivalent to intravenous therapy in the management of ARN. Oral valacyclovir as an outpatient therapy-with or without intravitreal foscarnet-can therefore be considered as an acceptable alternative to inpatient therapy required for intravenous treatment.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Baltinas J, Lightman S, Tomkins-Netzer O, et al. Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir. Am J Ophthalmol. 2018. PMID: 29447915. doi:10.1016/j.ajo.2018.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。